Education
About Us
Working with TipRanks
Follow Us
Alnylam Pharmaceuticals (ALNY)
NASDAQ:ALNY
ALNY Stock Chart & Stats
Day’s Range― - ―
52-Week Range$152.30 - $310.22
Previous CloseN/A
Volume78.96K
Average Volume (3M)911.06K
Market Cap
$40.26B
Enterprise Value$29.37B
Total Cash (Recent Filing)$2.63B
Total Debt (Recent Filing)$1.30B
Price to Earnings (P/E)―
Beta1.21
Next Earnings
Jul 31, 2025EPS Estimate
-0.66Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.44
Shares Outstanding130,388,400
10 Day Avg. Volume679,336
30 Day Avg. Volume911,056
Financial Highlights & Ratios
PEG Ratio-0.88
Price to Book (P/B)-182.78
Price to Sales (P/S)0.00
P/FCF Ratio-47.15
Enterprise Value/Market Cap0.73
Enterprise Value/Revenue3.25
Enterprise Value/Gross Profit14.54
Enterprise Value/Ebitda-86.87
Forecast
1Y Price Target
$328.41Price Target Upside6.38% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering23
Alnylam Pharma News
See All ALNY News
Bulls Say, Bears Say
Bulls Say
Market PotentialThe company estimates there are as many as 100k patients with TTR-CM in Europe, which indicates a large potential market.
Product LaunchThe Amvuttra launch in TTR-CM is anticipated to be the key value driver for Alnylam shares, with the majority of sales expected from the US.
Regulatory ApprovalFDA approved Amvuttra for TTR-CM to reduce cardiovascular mortality, cardiovascular hospitalizations, and urgent heart failure visits, setting it apart from other treatments.
Bears Say
Competitive RisksAlnylam will present its Ph3 TRITON-CM trial design for nucresiran in ATTR-CM, which can be dosed half as frequently as Amvuttra.
Market CompetitionThe enrolled population of patients were receiving robust background therapy, including TTR stabilizers like Pfizer’s tafamidis and SGLT2 inhibitors.
Market DynamicsAlnylam reported additional data for Amvuttra indicating strong effects in reducing all-cause mortality and cardiovascular mortality in the Ph3 HELIOS-B trial, yet competition from established TTR stabilizers remains.
Ownership Overview
0.42% Insiders
48.30% Mutual Funds
0.09% Other Institutional Investors
35.67% Public Companies and Individual Investors
ALNY FAQ
What was Alnylam Pharmaceuticals’s price range in the past 12 months?
Alnylam Pharmaceuticals lowest stock price was $152.30 and its highest was $310.22 in the past 12 months.
What is Alnylam Pharmaceuticals’s market cap?
Alnylam Pharmaceuticals’s market cap is $40.26B.
When is Alnylam Pharmaceuticals’s upcoming earnings report date?
Alnylam Pharmaceuticals’s upcoming earnings report date is Jul 31, 2025 which is in 42 days.
How were Alnylam Pharmaceuticals’s earnings last quarter?
Alnylam Pharmaceuticals released its earnings results on May 01, 2025. The company reported -$0.44 earnings per share for the quarter, beating the consensus estimate of -$0.89 by $0.45.
Is Alnylam Pharmaceuticals overvalued?
According to Wall Street analysts Alnylam Pharmaceuticals’s price is currently Undervalued.
Does Alnylam Pharmaceuticals pay dividends?
Alnylam Pharmaceuticals does not currently pay dividends.
What is Alnylam Pharmaceuticals’s EPS estimate?
Alnylam Pharmaceuticals’s EPS estimate is -0.66.
How many shares outstanding does Alnylam Pharmaceuticals have?
Alnylam Pharmaceuticals has 130,388,400 shares outstanding.
What happened to Alnylam Pharmaceuticals’s price movement after its last earnings report?
Alnylam Pharmaceuticals reported an EPS of -$0.44 in its last earnings report, beating expectations of -$0.89. Following the earnings report the stock price went down -3.081%.
Which hedge fund is a major shareholder of Alnylam Pharmaceuticals?
Currently, no hedge funds are holding shares in ALNY
Alnylam Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$328.41 (6.38% Upside)
$328.41 (6.38% Upside)
Blogger Sentiment
Bullish
ALNY Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 282.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $2.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.7%
Last 30 Days ▲ 4.0%
Last 30 Days ▲ 4.0%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
96.25%
12-Months-Change
Fundamentals
Return on Equity
-414.62%
Trailing 12-Months
Asset Growth
10.18%
Trailing 12-Months
Company Description
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
ALNY Company Deck
ALNY Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a generally positive trajectory for Alnylam Pharmaceuticals, characterized by strong revenue growth and successful product launches. Despite some uncertainties related to regulatory policies and increased R&D expenses, the company's strategic focus on TTR leadership and sustainable financial performance supports a positive outlook.Read More>ALNY Revenue Breakdown
67.90% Net product revenues
29.87% Net revenues from collaborations
2.22% Royalty revenue
ALNY Stock 12 Month Forecast
Average Price Target
$328.41
▲(6.38%Upside)